[Preparation, Characterization and Pharmacokinetic Study of Arginine Deiminase Lipid Nanoparticles].

Objective: To prepare and characterize D-alpha-Tocopheryl polyethylene glycol 1000 succinate (TPGS) modified arginine deiminase (ADI) sulfobutyl-β-Cyclodextrin liposome nanoparticles (ATCL), and to investigate the pharmacokinetic characteristics of ATCL in animals.

Methods: The reverse evaporation method was used to prepare ATCL, and the particle size and Zeta potential of ATCL were measured. Thiosemicarbazone-diacetylmonooxime colorimetric method was used to measure the activity of ADI.

[Pharmacokinetics of Curcumin Ethosomes in Rats ].

Objectives: To study the oral phamacokinetics of curcumin ethosomes in rats.

Methods: Pharmacokinetics parameters were detected by DAS 2.1.

[Pharmacokinetics and Bioequiavailability of Asparaginase in Asparaginase Nanospheres].

Objective: To determine the pharmacokinetics and bioequivalence of self-assembled hyaluronic acid-graft-poly (ethylene glycol)/hydroxypropyl-beta-cyclodextrin hollow nanospheres loaded with asparaginase (AHHPs) in SD rats.

Methods: AHHPs were prepared and observed under transmission electron microscopy. Its size, Zeta potential and entrapment efficiency were detected.

[A preliminary study of pharmacokinetics of evodiamine hydroxypropyl-β-cyclodextrin inclusion complex].

Objective: To compare the pharmacokinetic parameters of evodiamine hydroxypropyl-β-cyclodextrin inclusion complex and free evodiamine suspension in rats, and investigate the pharmacokinetic characteristics of evodiamine inclusion complex.

Methods: Both water solubility and cumulative release percentage of EHD were tested with evodiamine as the control. Blood samples were collected from the venous plexus of SD rats after intravenous administration with evodiamine inclusion complex and free evodiamine at 100 mg/kg (equivalent evodiamine dose).

[The Pharmacokinetics and Pharmacodynamics of Intravenous Uricase Multivesicular Liposomes].

Objective: To determine and compare the pharmacokinetics and pharmacodynamics of uricase-multivesicular liposomes (UOMVLs) with free uricase (UOX) in rats.

Methods: UOMVLs were prepared by the double emulsion method and confirmed with its entrapment efficiency, size and Zeta potential. Twelve healthy rats were randomly divided into two groups: one with i.

[Pharmacokinetics Study on Curcumin Hydroxypropyl-β-Cyclodextrin Phospholipid Complex in Rats].

Objective: To compare the in vivo pharmacokinetics of curcumin hydroxypropyl-β-cyclodextrin phospholipid complex, curcumin hydroxypropyl-β-cyclodextrin and curcumin phospholipid complex, and to discuss the advantage of hydroxypropyl-β-cyclodextrin phospholipid complex as carrier.

Methods: Drawing blood after SD rats were oral administered with the above preparations and free drug at 50 mg/kg( corresponding to curcumin) , and the blood concentration were determined by HPLC.

Results: The AUC0-∞ of curcumin hydroxypropyl-β-cyclodextrin phospholipid complex was(1 126.

[Pharmacokinetics and Intestinal Absorption of Curcumin Chitosan Hydrochloride Coated Liposome in Rats].

Objective: To investigate the pharmacokinetics and intestinal absorption characteristic of curcumin chitosan hydrochloride coated liposome(CCLP) in SD rats.

Methods: Blood samples were collected after oral administration. Pharmacokinetic parameters were analyzed by DAS program.

[Study on pharmacokinetics of demethoxycurcumin phospholipid complex in rats].

Objective: To study the pharmacokinetics of Demethoxycurcumin phospholipid complex in rats with oral administration.

Methods: Drawing blood from the SD rats after oral administration Demethoxycurcumin phospholipid complex and free demethoxycurcumin. The blood concentration were determined by HPLC.

[Pharmacokinetics study of curcumin solid lipid nanoparticles by intravenous injection in rats].

Objective: To study the intravenous pharmacokinetics of curcumin solid lipid nanoparticles in SD rats.

Methods: Rats were administrated with (iv) curcumin solid lipid nanoparticles and curcumin solution (8.0 mg/kg), respectively.

[Correlation between in vitro release and in vivo absorption of sustained-releasing tablets of neostigmine bromide].

Objective: To determine the correlation between in vitro release and in vivo absorption of sustained-releasing tablets of neostigmine bromide.

Methods: Water was used as dissolution medium to measured in vitro release of neostigmine bromide. After a single oral administration of 100 mg neostigmine bromide to rabbits, the plasma concentrations of neostigmine bromide in the rabbits were determined by HPLC.

[Pharmacokinetics of mestinon-phospholipid complex in rats].

Objective: To determine the pharmacokinetics characteristics of mestinon-phospholipid complex (PBPLC) in rats.

Methods: This study adopted a single-dose, randomized, open-label, two-period crossover trial design. Twelve healthy rats were randomly divided into two groups.

Improved biological properties and hypouricemic effects of uricase from Candida utilis loaded in novel alkaline enzymosomes.

Objective: Previous studies on various enzymosomes (functional lipid vesicles encapsulating an enzyme) have been mostly carried out in vitro and have focused on preserving catalytic activity and improving the stability of the enzyme. Until now, few studies have focused on their in vivo fate. Similarly, although we have previously reported the increased in vitro uricolytic activity (about 2.

[Preparation and quality control of pyridostigmine bromide orally disintegrating tablet].

Objective: To prepare orally disintegrating tablets containing pyridostigmine bromide and optimize formulations.

Methods: Solid dispersion was prepared using solvent evaporation-deposition method. The formulation was optimized by central composite design-response surface methodology (RSM plus CCD) with disintegration time as a reference parameter.

Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability.

A novel pyridostigmine bromide (PB)-phospholipid nanocomplex (PBPLC) was prepared to increase the bioavailability of PB. A central composite design approach was employed for process optimization. The physicochemical properties of PBPLC were investigated by means of differential scanning calorimetry, ultraviolet spectroscopy, Fourier transformed infrared spectroscopy and the n-octano/water partition coefficient.

[Bioequivalence of pyridostigmine bromide dispersible tablets in rabbits].

Objective: To compare the pharmacokinetic parameters of pyridostigmine bromide dispersible tablets and common tablets in rabbits.

Methods: Twelve rabbits were given an oral dose (60 mg) of pyridostigmine bromide dispersible tablets or common tablets in a randomized crossover study. The plasma concentration of pyridostigmine bromide was determined by reversed-phase ion pair chromatography.

[Pharmacokinetics and relative bioavailability of neostigmine bromide sustained-release tablets].

Objective: To study the pharmacokinetics and relative bioavailability of neostigmine bromide conventional tablets and sustained-release tablets in rabbits.

Methods: Six healthy rabbits were randomly divided into two groups for a cross self-contrast trial. RP-HPLC was used to detect plasma concentrations of neostigmine bromide.

[Pharmacokinetic study of a new chewing gum dextromethorphan delivery system].

Objective: To establish an high-performance liquid chromatography (HPLC)-based method for analysis of the pharmacokinetics and relative bioavailability of dextromethorphan chewing gum tablets in rabbits.

Methods: The pharmacokinetic parameters and the relative bioavailability of dextromethorphan chewing gum preparation in rabbits were compared with those of the commercially available chewing dextromethorphan tablets using 3P97 software.

Results: Pharmacokinetic analysis of the new dextromethorphan chewing gum tablets showed a AUC of 488.